Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on July 13, 2020, 12:42:10 pm
-
Shortening the standard 12-week regimen of Epclusa (sofosbuvir/velpatasvir) to just six weeks for those recently infected with hepatitis C virus (HCV) is associated with an unacceptably high rate of viral relapse after the end of therapy.
That’s according to a recent study presented by Gail Matthews, PhD, of the Kirby Institute at the University of New South Wales in Australia, at the 2020 Conference on Retroviruses and Opportunistic Infections in Boston last week.
The REACT study was a randomized controlled trial comparing a six-week (short) Epclusa regimen with a 12-week (standard) regimen among people who contracted HCV within the past 12 months, including people who inject drugs and people with HIV coinfection. The participants were randomized evenly into the two treatment arms.
Read more...
https://www.hepmag.com/article/shortened-epclusa-regimen-effective-recent-hep-c-infection